Clinical Trials Search

Official Title: Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Study Purpose: To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation.  

Status: Pending

Official Title: A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

Study Purpose: To assess whether ultrasound-facilitated, catheter-directed, thrombolysis and anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization.

Status: Recruiting

Official Title: HLX10-005-SCLC301-E: A Randomized, Open-label Study of HLX10 plus Chemotherapy (CarboplatinEtoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) ASTRIDE

Study Purpose: To take part in a clinical research study of an investigational new drug to treat extensive stage small cell lung cancer (ES-SCLC).  To see if HLX10 plus chemotherapy versus atezolizumab plus chemotherapy is efficacious 

Status: Recruiting

Official Title: A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Study Purpose: To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.

Status: Recruiting

Official Title: A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma

Study Purpose: To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.

Status: Recruiting

Official Title: A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL) 

Study Purpose: To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin 

Status: Recruiting

Official Title: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Study Purpose: This study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. 

Status: Recruiting

Official Title: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) Trial

Study Purpose: To evaluated safety and effectiveness of prophylactic LAAE for the prevention of ischemic stroke or systemic embolism in subjects undergoing cardiac surgery who have risk factors for AF and ischemic stroke

Status: Recruiting

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose: To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer.

Status: Recruiting